Shares of Nasus Pharma Ltd. (NYSEAMERICAN:NSRX – Get Free Report) traded down 0.3% on Thursday . The company traded as low as $3.01 and last traded at $3.07. 15,639 shares were traded during trading, a decline of 67% from the average session volume of 46,690 shares. The stock had previously closed at $3.08.
Analyst Upgrades and Downgrades
Separately, Citizens Jmp reduced their target price on shares of Nasus Pharma from $19.00 to $18.00 and set a “market outperform” rating on the stock in a research note on Thursday, March 26th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $18.00.
Read Our Latest Stock Report on Nasus Pharma
Nasus Pharma Stock Performance
Nasus Pharma Company Profile
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.
Featured Articles
- Five stocks we like better than Nasus Pharma
- Beyond the AI Trade: 3 Defensive Stocks Built for Stability
- MarketBeat Week in Review – 06/15 – 06/19
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
Receive News & Ratings for Nasus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nasus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
